Search Videos and More
News
Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial
News
Childhood leukemia care puts one in three families at risk of poverty
Dana-Farber-led study shows families develop food, housing insecurity or income loss during cancer treatment
News
Chemo-free Regimens Show Promise, Could Redefine Care for B-Cell Lymphomas
Dana-Farber studies of chemo-free, targeted-immunotherapy combinations show rapid, deep responses and potential for time limited care in B cell lymphomas
News
Dana-Farber Cancer Institute drives deep remissions in Waldenstrom’s with targeted, time limited therapies
Early phase results from Dana Farber suggest chemo free, time limited strategies may reduce the need for lifelong treatment in Waldenström’s
News
Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS)
Pivotal phase III VERONA trial results presented at the American Society of Hematology annual meeting show no overall survival improvement, but potential for sub-group benefit and no added side effects.
News
Sickle-cell disease associated with early onset of clonal hematopoiesis, a precancerous condition
The discovery, led by researchers at Dana-Farber, could pave the way for interventions to reduce the risk of blood cancers among people with sickle-cell disease.
News
Dana-Farber researchers to present findings at 2025 San Antonio Breast Cancer Symposium
Physician scientists from Dana-Farber Cancer Institute will present more than 50 research studies at the 48th annual San Antonio Breast Cancer Symposium, December 9-12.
Document
Treatment Guideline: Inavolisib, Palbociclib, and Fulvestrant for Hormone Receptor-Positive/HER2-negative Metastatic Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held meetings to discuss recommendations regarding the use of inavolisib, palbociclib, and fulvestrant in patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
News
Dana-Farber Research News 12.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 1 - 15.
Symposium
San Antonio Breast Cancer Symposium 2025
Many Dana-Farber clinician scientists are participating in the 2025 San Antonio Breast Cancer Symposium (SABCS), held December 9-12 in San Antonio Texas.
Video
ESMO25 Breast Cancer Highlights: ASCENT-03 and TROPION-Breast02
Harold Burstein, MD, PhD, and Ana Garrido- Castro, MD, discuss the ASCENT-03 and TROPION-Breast02 trials, investigating antibody-drug conjugates for triple-negative breast cancer.
Video
ESMO25 Breast Cancer Highlights: DESTINY-Breast11 & DESTINY-Breast05
Harold Burstein, MD, PhD, and Guilherme Nader Marta, MD, discuss the DESTINY-Breast11 and DESTINY-Breast05 trials examining trastuzumab deruxtecan in HER2-positive breast cancer.